BioLineRX
BLRX
13 hedge funds and large institutions have $45.2K invested in BioLineRX in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0.65% less ownership
Funds ownership: 1.1% → 0.45% (-0.65%)
7% less funds holding
Funds holding: 14 → 13 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
67% less capital invested
Capital invested by funds: $136K → $45.2K (-$90.4K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$30.7K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$842 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.99K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$2.81K |
| 4 |
Citigroup
New York
|
-$870 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$28 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
XT
1
XTX Topco
George Town,
Cayman Islands
| $25.3K | +$30.7K | +10,941 | New |
|
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $5.43K | -$2.81K | -1,000 | -30% |
|
|
3
BNP Paribas Financial Markets
Paris,
France
| $4.14K | +$842 | +300 | +20% |
|
4
Wells Fargo
San Francisco,
California
| $4.03K | – | – | – |
|
|
5
Citigroup
New York
| $3.99K | -$870 | -310 | -15% |
|
|
6
UBS Group
Zurich,
Switzerland
| $1.22K | -$3.99K | -1,422 | -73% |
|
|
NRG
7
Nemes Rush Group
Novi,
Michigan
| $575 | – | – | – |
|
|
NA
8
NewEdge Advisors
New Orleans,
Louisiana
| $247 | – | – | – |
|
9
Morgan Stanley
New York
| $230 | – | – | – |
|
10
Osaic Holdings
Scottsdale,
Arizona
| $59 | – | – | – |
|
11
Rockefeller Capital Management
New York
| $28 | – | – | – |
|
|
DB
12
Danske Bank
Copenhagen K,
Denmark
| $5 | – | – | – |
|
|
13
Citadel Advisors
Miami,
Florida
| – | -$104K | -36,651 | Closed |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | -$28 | -10 | Closed |
|
BLRX Hedge Fund Activity: Q1 2026 in Review
13 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2026, worth a combined $45.2K — down 67% from $136K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BLRX and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was XTX Topco, opening a new position worth an estimated $30.7K. The largest seller was Citadel Advisors, exiting entirely with an estimated $104K sold.
- 13 institutional investors held BioLineRX (BLRX) as of Q1 2026, down from 14 in Q4 2025.
- Funds reported $45.2K of BioLineRX stock for Q1 2026, down 67% quarter-over-quarter.
- 1 fund opened new BioLineRX positions in Q1 2026 and 2 closed out, a net change of -1 holder.
- The largest BioLineRX buyer in Q1 2026 was XTX Topco, an estimated $30.7K added.
- The largest BioLineRX seller in Q1 2026 was Citadel Advisors, an estimated $104K sold.
Based on aggregated 13F filings for Q1 2026.